Preferred Label : Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5;
NCIt synonyms : Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5; Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5; Ad5 CEA/MUC1/Brachyury Vaccine Tri-Ad5;
NCIt definition : A combination of three therapeutic cancer vaccines each containing a replication-defective,
oncolytic adenoviral serotype 5 (Ad5) and each encoding a different tumor-associated
antigen (TAA): human carcinoembryonic antigen (CEA), human glycoprotein mucin 1 (MUC1),
and human transcription factor brachyury, with potential immunostimulating and antineoplastic
activities. Upon subcutaneous administration, the Ad5 CEA/MUC1/brachyury vaccine Tri-Ad5
expresses the CEA, MUC1 and brachyury proteins. The expressed proteins may induce
a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing
CEA, MUC1 and brachyury, thereby resulting in both immune-mediated inhibition of tumor
cell proliferation and tumor cell death. CEA, MUC1 and brachyury are TAAs overexpressed
in various tumor types. The Ad5 viral genes early 1 (E1), early 2b (E2b), and early
3 (E3) are deleted in Tri-Ad5, which prevents anti-adenovirus immune responses.;
Molecule name : Tri-Ad5; Tri Ad5;
NCI Metathesaurus CUI : CL1793607;
Origin ID : C188365;
UMLS CUI : C5706498;
Semantic type(s)
- concept_is_in_subset
- has_target
